Maximum quantity allowed is 999
请选择数量
CAS RN: 5104-49-4 | 產品號碼: F0371
產品規格
| Appearance | White to Almost white powder to crystal |
| Purity(HPLC) | min. 98.0 area% |
| Purity(Neutralization titration) | min. 98.0 % |
| Melting point | 113.0 to 118.0 °C |
| Solubility in Methanol | almost transparency |
性質
| 熔點 | 113 °C |
| 水溶性 | Slightly soluble |
| 溶解性（可溶於） | Methanol |
GHS
| 圖形表示 |
|
| 信號詞 | Danger |
| 危險性說明 | H301 : Toxic if swallowed. H315 : Causes skin irritation. H319 : Causes serious eye irritation. |
| 防範說明 | P501 : Dispose of contents/ container to an approved waste disposal plant. P270 : Do not eat, drink or smoke when using this product. P264 : Wash skin thoroughly after handling. P280 : Wear protective gloves/ eye protection/ face protection. P302 + P352 : IF ON SKIN: Wash with plenty of water. P337 + P313 : If eye irritation persists: Get medical advice/ attention. P305 + P351 + P338 : IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. P362 + P364 : Take off contaminated clothing and wash it before reuse. P332 + P313 : If skin irritation occurs: Get medical advice/ attention. P301 + P310 + P330 : IF SWALLOWED: Immediately call a POISON CENTER/doctor. Rinse mouth. P405 : Store locked up. |
相關法規
| RTECS # | DU8341000 |
運輸資料
| UN編號 | UN2811 |
| 類別 | 6.1 |
| 包裝類別 | III |
| HS編碼* | 2916.39-000 |
Application
Flurbiprofen: A Racemic Non-Selective and Non-Steroidal Anti-Inflammatory Drug (NSAID)
Flurbiprofen is a racemic non-selective and non-steroidal anti-inflammatory drug (NSAID) of the 2-arylpropionic acid (2-APA) class, such as ibuprofen [I0415], (S)-ibuprofen [I0549], (±)-naproxen [M1220] and (S)-naproxen[M1021]. Only (S)-flurbiprofen [CAS: 51543-39-6] inhibited prostaglandin biosynthesis in vitro. Therefore, (S)-flurbiprofen has been shown to have both antiinflammatory and antinociceptive effects, whereas (R)-flurbiprofen [CAS: 51543-40-9] is antinociceptive but not antiinflammatory. In 2000s, some studies have shown that (R)-flurbiprofen is a potent reducer of levels of β-amyloid (Aβ). Hence, (R)-flurbiprofen had been under development for the treatment of Alzheimer's disease; however this development was discontinued in 2008. (The product is for research purpose only.)
References
- Flurbiprofen: a review of its pharmacological properties and therapeutic use in rheumatic diseases
- Flurbiprofen (a review)
- New insights into the site and mode of antinociceptive action of flurbiprofen enantiomers (a review)
- NSAIDs and enantiomers of flurbiprofen target γ-secretase and lower Aβ42 in vivo
- Activity of flurbiprofen and chemically related anti-inflammatory drugs in models of Alzheimer's disease (a review)
- Drug evaluation: (R)-flurbiprofen--an enantiomer of flurbiprofen for the treatment of Alzheimer's disease (a review)
- Fluorescent Dye Cocktail for Multiplex Drug￢Site Mapping on Human Serum Albumin
- High-resolution and high-throughput protocols for measuring drug/human serum albumin interactions using BIACORE
- Biosensor Analysis of the Interaction between Immobilized Human Serum Albumin and Drug Compounds for Prediction of Human Serum Albumin Binding Levels
- Characterizing a drug's primary binding site on albumin
- Structural basis of the drug-binding specificity of human serum albumin
ApplicationBinding of Flurbiprofen to Human Serum AlbuminFlurbiprofen is known to have affinity for Human Serum Albumin (HSA) and to bind (interact) to drug binding site II on HSA. Those were confirmed using our ibuprofen with Surface Plasmon Resonance (SPR) and a method using fluorescent probes. 【SPR】Dose responses of flurbiprofen to HSA were confirmed by SPR. Biacore, as a SPR biosensor, was used for the assay, according to the user’s guide of the instrument.
＜Assay condition＞ Sensor Chip: Series S Sensor Chip CM5, Immobilization: HAS (Amine Coupling method), Buffer : 5%DMSO in PBS. ＜Result＞ “Square wave” sensorgrams were exhibited at each concentration, and concentration dependent binding of flurbiprofen to HSA was confirmed. 【Method using fluorescent probes】The drug biding site of flurbiprofen was confirmed using fluorescent probes which bind to drug binding site on HSA. Dansylamide (DNSA) [D5405] was used as fluorescent probe for site I, and dansylglycine (DNSG) [D5406], BD140 [D4898] were used as fluorescent probes for site II, and then bindings to site I and site II were confirmed.
＜Assay condition＞ Buffer: 1 % DMSO in phosphate buffer (pH 7.2 - 7.5); HSA: 5 µM (DNSA), 20 µM (DNSG, BD140) (50 µL/well) (Fatty acid free HSA is recommended.); Flurbiprofen: each concentration (50 µL/well); DNSA: 80 µM, DNSG: 20 µM, BD140: 20 µM (50 µL/well); Incubation: 20-25 °C for 30 min; Measurement: plate-reader with excitation = 365 nm and emission = 480 nm (DNSA, DNSG), with excitation = 365 nm and emission = 585 nm (BD140). ＜Result＞ As shown in upper diagram, inhibition against binding of dansylglycine and BD140 which are fluorescent probes for site II by flurbiprofen was confirmed. And also, little or extremely weak inhibition against binding of dansylamide which is fluorescent probe for site I was confirmed. In these ways, our flurbiprofen can be used for study of interaction with HSA. Also, DNSA [D5405], DNSG [D5406] and BD140 [D4898] can be used for study of drug binding site on HSA.References
考研文獻
文章/手冊
產品文件 （部分產品的分析圖譜無法提供，敬請諒解。）
SDS
請選擇語言。
請求的SDS不可用。
如需更多幫助，請聯繫我們 。
產品規格
檢驗報告(CoA)及其他文檔
請輸入批號
輸入的批號不正確
示例 CoA
可下載CoA示例。注：該示例可能非最新批次的CoA。
目前沒有該產品的 CoA 示例。
分析圖譜
請輸入批號
輸入的批號不正確
很抱歉，您搜索的分析圖譜無法提供。